Remediation for Mild Cognitive Deficits After Cancer

NCT ID: NCT04808674

Last Updated: 2023-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-17

Study Completion Date

2025-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer survival rates have improved significantly over the past decades and patients now experience a number of side effects including cancer-related cognitive impairment (CRCI): problems with memory, executive function, attention, and difficulties performing two tasks at the same time. The frequency of CRCI in cancer patients is estimated to be between 10 to 40%, and more than 50% of patients describe difficulties in their daily life. These cognitive difficulties negatively impact the patient's quality of life as well as that of their family, and can also have negative consequences for their social and professional reintegration once cancer treatment is finished. Despite an increasing number of studies on CRCI, a standard of care for patients with CRCI after breast cancer is yet to be established. In the absence of clear directives, and in an attempt to respond to the increasing demand to provide care for breast cancer patients with CRCI, physical medicine and rehabilitation units in France have started providing day-hospital multidisciplinary interventions. The objective of this project is to use the single case experimental design method to investigate the efficacy of two such rehabilitation programs: a group-based program and a one-on-one program.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Remediation Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group-based cognitive remediation program

Patients are admitted to the day hospital 2 days a week for 6 weeks and participate in a group-based (4 patients per group) rehabilitation program conducted by a multidisciplinary team including a PMR doctor, a neuropsychologist, an occupational therapist, and a physical activity monitor).

Group Type EXPERIMENTAL

Cognitive remediation program

Intervention Type BEHAVIORAL

Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer

One-on-one cognitive remediation program

Patients are admitted to the day hospital 5 days a week for 6 weeks and participate in a one-on-one intensive rehabilitation program conducted by a multidisciplinary team including a speech therapist, neuropsychologist, occupational therapist, physiotherapist, physical activity monitor and a psychologist.

Group Type EXPERIMENTAL

Cognitive remediation program

Intervention Type BEHAVIORAL

Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive remediation program

Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treated in the past for breast cancer with chemotherapy, surgery, and / or radiotherapy,
* Admitted as a day patient at the Henry Gabrielle Hospital or the Pontchaillou CHU Hospital during the study,
* Given free, informed consent in writing after being informed orally and in writing of the how the study will proceed.

Exclusion Criteria

* Presence of another active cancer,
* Ongoing chemotherapy and/or radiotherapy treatment,
* Active progression of breast cancer,
* History of neurological or psychiatric conditions,
* Major disturbances in comprehension that prevent them giving free, informed consent,
* Pregnant, parturient or breastfeeding women,
* Person under a legal protection measure such as guardianship or curatorship,
* People not affiliated to a social security scheme (French Social Security) or beneficiaries of a similar scheme.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sophie JACQUIN-COURTOIS, PhD

Role: PRINCIPAL_INVESTIGATOR

Service de médecine physique et de réadaptation, HCL,

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospices Civils de Lyon - Groupement hospitalier sud - Hôpital Henry Gabrielle - Service de médecine physique et de réadaptation

Lyon, , France

Site Status RECRUITING

Hôpital Pontchaillou - Service de Médecine Physique et de Réadaptation

Rennes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sophie JACQUIN-COURTOIS, PhD

Role: CONTACT

04.78.86.50.64

Mélanie COGNÉ, MD

Role: CONTACT

02.99.28.42.18

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sophie JACQUIN-COURTOIS, PhD

Role: primary

0478865064

Mélanie Cogné, MD

Role: primary

0299284218

Isabelle Bonan, PhD

Role: backup

0299284218

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A00798-33

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL20_1018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early-phase Telecare Programs for Minor Stroke
NCT06306144 NOT_YET_RECRUITING NA